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Abstract 
We measured the level of reduced glutathione (GSH) and oxidized glutathione (GSSG) in normal and oncogene-transformed NIH/3T3 fibroblasts 
and 32D hematopoietic cells. NIH/3T3 cells transformed by the activated oncogenes erbB, src, and raf, showed increased levels of GSH with 
concomitant alterations in the levels of GSH-related enzymes. Transfection and over-expression f a synthetic gene coding for a phosphotyrosine 
protein phosphatase (PTPase), which inhibited the proliferation of normal and transformed NIH/3T3 cells, was accompanied by a decrease in GSH 
levels in normal and erbB-transformed fibroblasts, and by an increase in src and raf transformants. Among GSH-related enzymes, only 
y-glutamylcysteine synthetase was altered in normal and erbB-transformed NIH/3T3 fibroblasts following PTPase transfection. Therefore, tyrosine 
phosphorylation could be selectively involved in the regulation of GSH metabolism in normal and oncogene-transformed NIH/3T3 fibroblasts, 
possibly by a dual-type ffect on receptor/oncoprotein-mediated mi ogenic signal transduction. However, no relationship was observed between the 
GSH and PTPase effect on cell growth, either after oncogene transfection or PTPase transfection. Moreover, the changes in GSH metabolism were 
specifically related to cell lineage. In fact GSH and related enzymes did not change in 32D hematopoietic cells transformed by the same activated 
erbB oncogene and in those - normal or transformed - over-expressing the PTPase: in these cells also, over-expression f the PTPase gene was not 
accompanied by growth inhibition. 
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I. Introduction 
Among the different biochemical mechanisms control- 
ling the proliferation of normal and transformed cells, 
protein tyrosine phosphorylation is of utmost impor- 
tance. We recently demonstrated that transfection and 
over-expression of a synthetic gene coding for a novel 
phosphotyrosine protein phosphatase (hereafter referred 
to as PTPase) resulted in the inhibition of proliferation 
of normal, and of erbB-, src- and raf-transformed NIH/ 
3T3 fibroblasts [1,2]. Transfection and over-expression 
of PTPase did not affect he growth of normal or trans- 
formed 32D hematopoietic cells, thus suggesting a selec- 
tive effect on tyrosine-phophorylated protein(s) control- 
ling the proliferation of NIH/3T3 cells [2]. 
NIH/3T3 fibroblasts transformed by a single activated 
oncogene also proved useful in studying the relationship 
between alterations of glutathione (GSH) metabolism 
and oncogenic transformation. Thus, we recently dem- 
onstrated that NIH/3T3 cells transformed by the erbB, 
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Abbreviations: GSH, reduced glutathione; GSSG, oxidized glutathione; 
GST, glutathione-S-transferase (EC 5.1.18); GR, glutathione r ductase 
(EC 1.6.4.2); y-GCS, y-glutamyl cysteine synthetase (EC 6.3.2.2). 
src, raf, and ras oncogenes, but not those transformed by 
sis or dbl, showed peculiar alterations of GSH metabo- 
lism: GSH was elevated in erbB, src, rafand ras transfor- 
mants, whereas GSSG increased significantly only in src 
transformants [3]. The activity of the synthetic enzyme 
y-glutamylcysteine synthetase (y-GCS) was inversely re- 
lated to GSH content, suggesting a mechanism ofdown- 
regulation; the activity of GSH reductase (GR) was di- 
rectly related to GSSG levels [3], and GSH-S-transferase 
decreased, thus indicating a decrease in the detoxifica- 
tion processes. Thus, neoplastic transformation byeach 
oncogene caused specific alterations to GSH metabo- 
lism, suggesting a relationship between the biochemical 
mechanism(s) responsible for transformation a d those 
causing alterations in GSH metabolism that, in turn, are 
related to resistance to the killing effects of anti-neoplas- 
tic drugs and ionizing radiations [4-7]. 
Considering these previous results, we performed a
study to relate GSH metabolism with PTPase activity 
and transformation in order to determine whether pro- 
tein tyrosine phosphorylation processes could be in- 
volved in the specific alterations of GSH metabolism in
oncogene-transformed cells. Data have been reported on 
the involvement of GSH on the phosphorylation/ 
dephosphorylation mechanisms by thiol disulfide ex- 
change [8]. We monitored the metabolism of GSH in 
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NIH/3T3 fibroblasts and in 32D hematopoietic cells, ei- 
ther normal or oncogene-transformed, before and after 
transfection and over-expression f the synthetic PTPase 
gene. 
2. Materials and methods 
2. l. Materials 
All enzymes, coenzymes and substrates were from Boehringer 
(Mannheim, Germany). All other chemicals were supplied by Merck 
(Darmstadt, Germany). 
2.2. Cells 
Normal NIH/3T3 fibroblasts, 32D, immature myeloid murine cells, 
and their oncogene-transformed counterparts were obtained from the 
Laboratory of Cellular and Molecular Biology of the National Cancer 
Institute (NIH, Bethesda, MD, USA) [9-12]. 
2.3. Transfection and over-expression of the synthetic PTPase gene 
A gene coding for the bovine isoform of PTPase was synthetized in
our laboratory, and was transfected into normal and oncogene-trans- 
formed cells. Transfection experiments were performed as follows; 10 
/.tg of the plasmid, termed pSVPTP (generated in our laboratory as 
described by Ramponi et al. [1]) and 0.5/.tg of the plasmid termed 
pK0neo (i.e. the function coding for resistance to antibiotics uch as 
neomycin and geneticin (G-418 Sigma Chem. Co.), used to select rans- 
fection-positive clones, and, when transfected alone, as control, as de- 
scribed in Ramponi et al. [1]) were used for transfecting 1.5 million cells 
on a 100-mm plate. Selection of stable antibiotic-resistant clones was 
performed by supplementing the medium with 500/lg/ml of antibiotic 
(G-418). mRNA analysis was performed using the 32p-labelled PTPase 
synthetic DNA as a probe, under high stringency conditions (2 x SET 
at 65°C). Total RNA preparation and Northern blot analysis were 
performed as previously reported [11]. Both normal and transformed 
cells were also transfected with pK0neo alone. Stable over-expression 
of PTPase was assessed by ELISA as described in Ruggiero et al. [11], 
and the level of the enzyme remained approximately the same for up 
to 2 months. In this study we used transfected clones that expressed 
PTPase as follows (fold increase over control values): normal NIH/3T3, 
2 fold; erbB-NIH/3T3, 6 fold; src-NIH/3T3, 44 fold; raf-NIH/3T3, 21 
fold; normal 32D, >50 fold, erbB-32D, >50 fold. 
2.4. Glutathione determinations 
Cells (4-10 x 106) were centrifuged in a microcentrifuge (12,550 x g 
for 15 min at 4°C), the precipitate was directly dissolved in 0.5 ml 5% 
HC104 and the cells were lysed by sonication. Following centrifugation, 
the supernatant was assayed for GSH and GSSG by HPLC as described 
by Reed and Fariss [13]. Briefly, it was neutralized by 2 M K2CO 3, then, 
50 gzl of 300 mM iodioacetic acid, and 200/zl of 0.7 M KHCO3 were 
added to 0.5 ml of extract. The resulting alkaline solution was incubated 
for 1 h at room temperature in complete darkness. 0.1 ml of 5% (v/v) 
fluorndinitrobenzene was added to the supernatant, which was then 
stored at 4°C overnight. The solutions were analyzed by liquid chro- 
matography (Beckman Gold System equipped with an NEC/PC8201H 
computer, a Shimadzu C-R6A chromatopac integrator, and a Bio-Sil 
NH 2 90-5S Bio-Rad column). The 2,4-dinitrophenyl derivatives were 
detected at 365 nm. GSH and GSSG were quantified relative to stand- 
ards by integration. 
2.5. Enzyme assay 
Cells (4-10 x 10 6) were  centrifuged and the precipitate was dissolved 
using 0.5 mt 150 mM Tris buffer containing 5 mM MgC12, 2 mM 
1,4-dithiothreitol at pH 7.4. Cells were lysed by sonication at 4°C. The 
homogenate was centrifuged at 15,000 x g for 25 min. The activity of 
GR was determined by the method of Goldberg and Spooner [14]. The 
activity of y-GCS was assayed by Seeling's method [15]. GST was 
assayed with the method of Habig et al. [16]. All enzymatic activities 
were  measured at 37°C using a Kontron (Uvikon 710) spectrophoto- 
meter, and were expressed in terms of micromoles per min per mg of 
total protein. The protein concentration was determinated by 
Bradford's method [17]. Bovine serum albumin (Sigma Chemical Co.) 
was used as the control standard. 
2.6. Statistical analysis 
The significance of the disparities between the observed and normal 
means was evaluated using Student's t-test. A difference of P < 0.05 
was considered significant. 
3. Results and discussion 
As a first step in our study of GSH metabolism, we 
monitored the effect of PTPase over-expression  the 
different components of the GSH system in normal and 
NIH/3T3 fibroblasts transformed by the oncogenes, 
erbB, raf and src, which code for transforming proteins 
interfering with signal transduction [18]: (i) v-erbB en- 
codes a truncated form of the EGF receptor; (ii) the 
product ofsrc is a non-receptorial tyrosine kinase associ- 
ated with the inner layer of the membrane; (iii) rafcodes 
for a cytoplasmic serine/threonine kinase bearing homol- 
ogy of sequence and function with protein kinase C. 
Table 1 shows that GSH increased in ceils transformed 
by the oncogenes, erbB, raf, and src, as compared with 
normal fibroblasts by 93, 133 and 66%, respectively. 
PTPase over-expression significantly reduced GSH levels 
in normal cells and in erbB transformants byabout 50%, 
while in raf and src transformants he GSH level in- 
creased by 23 and 50%, respectively, as compared with 
normal and transformed fibroblasts not over-expressing 
the PTPase. Since PTPase inhibited the proliferation of 
all the transfected lines approximately to the same extent 
[1,2], these results demonstrate a dissociation between 
the effects of PTPase on cell growth and GSH levels. It 
could be hypothesized that the different oncogenes used 
distinct mechanisms leading to the increase in GSH; 
dephosphorylation f tyrosine residues proved critical 
for GSH levels to decrease in normal and erbB-trans- 
formed NIH/3T3 fibroblasts, while in src and raf trans- 
formants, tyrosine dephosphorylation appeared to fa- 
vour an increase in GSH. Table 1 shows that the GSSG 
content also increased in all the transformed lines, but 
this increase was statistically significant only in src trans- 
formants. Transfection and over-expression of PTPase 
caused changes in GSSG content in normal and 
transformed fibroblasts, but these alterations were not 
statistically significant. These results indicate that over- 
expression of PTPase did not enhance oxidative mecha- 
nisms. These was further confirmed by the redox index 
(ratio of GSSG/GSH; marker of the intracellular oxida- 
tive status) that was similar in all the lines. 
Having observed these variations of the components 
of the GSH system, we studied the activity of the en- 
zymes involved in GSH metabolism. Table 2 shows the 
complex alterations of ),-GCS, GST and GR specific 
activities occurring in transformed cells either wild-type 
or over-expressing PTPase. 7"-GCS activity, i.e. the activ- 
ity of the synthetic enzyme which represents a rate-limit- 
ing step in intracellular GSH synthesis, significantly 
decreased in the transformed cells, and we previously 
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Table 1 
Level of GSH system components in normal, transformed NIH/3T3 
fibroblasts, normal and erbB-transformed 32D hematopoietic cells: ef- 
fect of PTPase synthetic gene over-expression 
Cell line GSH GSSG GSSG/GSH 
NIH 30 f 2 2.0 f 0.5 0.07 k 0.007 
NIH/PTPase 15 f 1* 1.5 + 0.4 0.10 f 0.015 
erbB-NIH 58 f 6* 3.0 + 0.3 0.05 + 0.009 
erbB-NIHl 
PTPase 37 f 4” 2.0 + 0.3 0.05 k 0.005 
src-NIH 70 f 6* 6.0 f 0.6* 0.08 + 0.006 
src-NIH/PTPase 90 f 4++* 7.0 f 0.6* 0.07 f 0.004 
ruf_NIH 50 f 5** 3.0 t 0.1 0.06 +_ 0.002 
raf_NIHIPTPase 77 f 7’* 3.5 + 0.5 0.05 f 0.006 
32D 160 k 17 16.0 k 2.0 0.10 f 0.01 
32D/PTPase 155 f 30 20.0 f 3.0 0.12 f 0.02 
erbB-32D 160 f 24 20.0 f 3.0 0.12 + 0.02 
erbB-32Dl 
PTPase 180 f 30 17.0 f 3.0 0.09 * 0.01 
GSH and GSSG are expressed as nmol/mg protein. Data are 
means f S.E.M. of four (32D) and five (NIH/3T3) experiments, each 
performed on duplicate samples. Significant differences: from NIH/3T3 
cells, *P < 0.005, **P < 0.05; from erbB-transformed cells, “P < 0.05; 
from src-transformed cells, +‘P c 0.05; from raftransformed cells, 
+P < 0.05. 
interpreted this decrease as a negative feedback mecha- 
nism brought about by elevated GSH content [3]. 
PTPase transfection and over-expression caused y-GCS 
activity to increase in normal and e&B-transformed fi- 
broblasts (i.e. in those cells where PTPase over-expres- 
sion reduced GSH levels as compared with cells not over- 
expressing the PTPase), whereas SK and raf transfor- 
mants were unaffected. In the presence of over-expressed 
PTPase, however, y-GCS activity remained low even if 
the GSH level increased. GST activity (which is the enzy- 
matic activity involved in the GSH-related detoxication 
processes) decreased in all the transformed lines as com- 
pared with normal NIH/3T3 fibroblasts; transfection 
and over- expression of PTPase, however, did not signif- 
icantly change the specific activity of this enzyme neither 
in normal nor in transformed cells. This may indicate 
that detoxication mechanisms decreased in transformed 
cells. This in turn could be a cause for the increased GSH 
which would be less utilized. The specific activity of GR, 
the enzyme involved in the reduction of GSSG to GSH, 
showed a significant increase in src-transformed fibro- 
blasts. PTPase transfection and over-expression did not 
cause GR activity to change significantly as compared 
with either normal or transformed wild-type fibroblasts. 
The GR increase in src transformants (either over-ex- 
pressing or not the PTPase gene) could be explained by 
substrate induction since a marked increase in GSSG 
content was found only in these cells. The main conclu- 
sion from these results is that only in e&B-transformed 
fibroblasts and in normal NIH/3T3 fibroblasts did over- 
expression of PTPase decrease the level of GSH and 
cause y-GCS activity to increase, whereas in src and raf 
transformants over-expression of PTPase increased 
GSH content. 
In order to clarify the observed effects of PTPase on 
GSH metabolism in the different transformants, we stud- 
ied another cell line, i.e. the hematopoietic cell line 
termed 32D, either normal or transfected by the same 
activated erbB oncogene, over-expressing or not the 
PTPase. This immature, non-tumorigenic myeloid line is 
strictly dependent on interleukin-3 for proliferation and 
survival [ 121. Interleukin-3 requirement could be abro- 
gated by oncogene-induced transformation (i.e. by genes 
such as erbB, abl, and src [12,19]). In this cell line, 
PTPase over-expression did not influence cell prolifera- 
tion, neither of normal nor of transformed cells [2]. Thus, 
it was of interest to determine whether it affected GSH 
metabolism in normal or erbB-transformed 32D cells, i.e. 
in the hematopoietic counterpart of those NIH/3T3 lines 
the GSH metabolism of which was altered by PTPase 
over-expression. Table 1 shows that normal and erbB- 
transformed 32D cells had identical levels of GSH, 
GSSG, and GSSG/GSH. Since erbB-transformed 32D 
cells are fully malignant, these data confirm that altera- 
tions in GSH metabolism observed in some oncogenic 
transformants were specifically correlated not only with 
particular oncogenes, but also with a specific cell line, as 
they were not trivial epiphenomena of malignant trans- 
formation. These results (i.e. alterations of GSH metab- 
olism specifically associated with particular oncogenes 
and cell types) are in agreement with a previous observa- 
tion reporting altered content of GSH only in certain 
tumors [20]. Transfection and over-expression of PTPase 
to a level even higher than that achieved in NIH/3T3 
cells, did not alter GSH metabolism, neither in normal 
Table 2 
Specific activity of GSH-related enzymes in normal, transformed NIH/ 
3T3 fibroblasts, normal and erbB-transformed 32D hematopoietic cells: 
effect of PTPase synthetic gene over-expression 
Cell line GST GR y-GCS 
NIH 0.064 f 0.003 0.052 f 0.005 0.15 f 0.010 
NIH/PTPase 0.060 f 0.004 0.040 k 0.003 0.20 + 0.020* 
erbB-NIH 0.035 f 0.003**0.060 f 0.002 0.11 f 0.006* 
erbB-NIHI 
PTPase 0.040 f 0.003**0.050 ? 0.004 0.15 f 0.009” 
src-NIH 0.030 f 0.002**0.080 f 0.004* 0.10 f 0.004** 
src-NIHIPTPase 0.020 +_ 0.001**0.075 ? 0.004* 0.11 k O.OlO* 
rafNIH 0.035 f 0.002**0.060 f. 0.002 0.12 f 0.002* 
rajNIH/PTPase 0.045 ?r 0.007* 0.060 f 0.005 0.10 f 0.005** 
32D 0.040 f 0.004 0.130 f 0.010 0.11 f 0.010 
SZD/PTPase 0.050 f 0.006 0.120 + 0.020 0.10 f 0.010 
erbB-32D 0.055 + 0.010 0.120 f 0.020 0.11 f 0.010 
erbB-32Dl 
PTPase 0.040 + 0.004 0.110 + 0.010 0.12 f 0.010 
Specific activity of enzymes are expressed as pmol per min per mg total 
protein. Data are means f S.E.M. of four (32D) and five (NIH/3T3) 
experiments, each performed on duplicate samples. Significant differ- 
ences: from NIH/3T3 cells, *P < 0.005, **P < 0.001; from erbB-trans- 
formed cells, o P < 0.05. 
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nor in transformed 32D cells. Consistent with these re- 
sults, PTPase over-expression did not change the activity 
of GSH-related enzymes as evidenced in Table 2. Taken 
together these data indicate that the effect of PTPase 
over-expression on GSH metabolism was selective for 
normal and oncogene-transformed fibroblasts, and was 
not related to the rate of proliferation per se. 
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